INTRODUCTION
We have recently reported that conditioned media prepared from a variety of human tissues and cultured cancer cells exhibit two distinct types of colonystimulating factor (CSF)l which can be separated by isoelectrofocusing and gel filtration chromatography. CSF I shows heterogeneity on IEF with pI in the range of 3.6-4.7 and has a molecular weight of 50,000. CSF II appears as a single peak with pI of 5.7 and has a molecular weight of 27,000. CSF I stimulates mouse bone marrow CFU-C but has little or no activity in human marrow while CSF II is more active in human than in mouse marrow (1) .
A number of important questions are raised by our observations particularly concerning the relationship between these two types of CSF (2) . The preparation ofmouse and human bone marrow cells and the morphological identification of colonies have been described previously (1) . A unit of CSF activity is arbitrarily defined as the amount of CSF which stimulates the formation of one colony under the specified assay conditions. Production of antibodies against CSF I and II in rabbits. Purified CSF I (0.1 mg, 7 x 106 U) and partially purified CSF II (1.0 mg, 1.2 x 10' U) from cultured human pancreatic carcinoma (MIA PaCa-2) (3) were used to immunize rabbits according to procedures described previously (4) . Preimmunized and immunized sera were treated with 33% saturated ammonium sulfate, and the globulin fraction was subjected to DEAE-cellulose chromatography according to the standard procedure. The purified IgG fractions (preimmunized and immunized) were reconstituted to the original serum volume in nornal saline solution.
Cross-inhibition by antibodies. The antibodies thus prepared were used to study the cross-inhibition among dif- (6) . The iodinated 125I-CSF I was then purified on a Sephadex G-25 column (PD-10) followed by an Ultrogel AcA column (10 x 110 mm, Column volume, 110 ml) equilibrated with phosphate-buffered saline. The 125I-CSF I thus prepared had a specific radioactivity of 105 cpm/ng and at least 80% of the initial biological activity. Iodination efficiency was -10%.
Radioimmunoassay (RIA) of CSF I. CSF samples from different sources were properly diluted with RIA buffer (50 mM phosphate buffer pH 6.5 containing 0.2% bovine serum albumin, 0.1% NaN3, and 0.01% ethylene glycol 6000). 100 ,ul of sample, 10 ,ul of 125I-CSF I (18,000 cpm) in RIA buffer, and 25 ,ul of diluted anti-CSF I antibody were mixed in that order. RIA buffer was added to a final volume of 200 ,ul. The radioactivity of all samples was counted and the samples were then incubated overnight at 4°C. Undiluted control IgG (100 ,ul) was added to each tube, followed by 200 ,ul of saturated ammonium sulfate solution (pH adjusted to 7.0). The precipitates were left in ice for 30 min and then centrifuged at 10,000 rpm (Sorvall RC-5B, SS-34 Rotor). The supemates were removed and the radioactivity of the precipitates measured in a gamma counter (Nuclear Chicago Des Plaines, Ill.). The amount of anti-CSF I antibody used in the assay was equivalent to the concentration which produced a bound/free ratio (B/F) of -1.0. In our study, the B/F ratio from one batch of 1251 CSF I and anti-CSF I could be kept relatively constant for -1 wk.
Competitive binding of CSF I and CSF IL. CSF I from several sources including MIA PaCa-2 cells, human lung, and human placenta were partially purified by isoelectrofocusing and gel filtration chromatography as described previously (1) . Samples containing CSF activities in the range of 0.1 to 1,000 U in 100 ,ul of RIA buffer were used in the RIA competitive binding studies as described above. Partially purified CSF II from MIA PaCa-2 cells was also used to compare the competitive binding of CSF I and II to the anti-CSF I antibody.
Fractionation of human bone marrow cells by sedimentation at unit gravity. The preparation of human bone marrow cells and fractionation by sedimentation velocity on the Sta-Put apparatus have been described previously (7) . A total of 1.4-1.8 x 108 cells were layered over a continuous bovine serum albumin gradient of 0.5 to 2.0% and allowed to sediment for 3.5 h at 4°C. Cell fractions were collected from the bottom of the separation chamber and assayed for CFU-C with either CSF I or CSF II obtained from human lung conditioned medium (8) after isoelectrofocusing and gel filtration chromatography (1) .
RESULTS
Inhibition ofCSF I and II by antibodies. As shown in Fig. 1 , when CSF I was incubated with control IgG, anti-CSF I IgG, and anti-CSF II IgG, the activity as assayed on mouse marrow cells was inhibited only by anti-CSF I; there was no inhibition by anti-CSF II or control IgG. Similarly, the activity of CSF II as assayed on human bone marrow cells was specifically inhibited by anti-CSF II antibody. The results clearly indicate that CSF I and II are immunologically distinct. Anti-CSF I also cross-inhibited CSF I from human lung, placenta, and urine, but showed no effect on CSF from mouse lung and mouse L cells (Table I) .
Competitive binding of CSF I and Il-RIA. Using anti-CSF I antibody and radioiodinated 1251-CSF I, an Fig. 3 . When CSF II was used to assay the various fractions, two broad CFU-C peaks were observed. One peak, with a sedimentation velocity of8-8.5 mm/h, formed colonies by day 7 of culture and another peak sedimenting at 6.5 mm/h formed colonies by day 13. In contrast, CSF I stimulated little or no colony formation in any fractions on day 7. Instead, a new, broad CFU-C peak appeared between 7 and 9 mm/h on day 13 of culture.
Colony morphology in fractionated marrow, in response to the two types of CSF, was also different. Colonies formed in response to type II CSF were predominantly granulocytic on day 7 (84%), becoming predominantly macrophagic by day 13. Colonies formed in response to type I CSF on day 13 were 70% granulocytic in the low-sedimenting (6.8 mm/h) and 42% granulocytic in the high-sedimenting (8.5 mm/h) fractions. This was still more than double the percentage seen with type II CSF in the same fractions. (8), two CFU-C peaks are observed (7), one sedimenting at -8-8.5 mm/h and forming colonies after 7 d of culture, and a second sedimenting at 6.5 mm/h and not forming colonies until at least the 11th d of culture. A similar CFU-C profile was obtained here using human lung CSF II. In contrast, when lung CSF I was used, essentially one CFU-C peak was obtained, exhibiting colonies on day 13 but having an average sedimentation velocity different from that of the 13-d peak seen with CSF II. Additionally, whereas most of the 13-d colonies with CSF II were macrophagic, those with CSF I were 42-80% granulocytic. The virtual absence of 7-d colonies with CSF I offers a good explanation as to why "human activity" of CSF I has not been evident in the routine 7-d assay in the past.
It is clear from our studies that CSF I and II are biochemically and immunologically distinct and appear to have a different CFU-C specificity. Perhaps more important is that the so called "mouse active" CSF I is also "human active" and should be looked at in a different perspective.
